Avidity Biosciences 12M share Secondary priced at $17.25

The deal size was increased to $207M in common stock from $150M in common stock. Cowen, Evercore ISI and Wells Fargo acted as joint book running managers for the offering.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on RNA:

• Avidity Biosciences announces $150M common stock offering
• Avidity Biosciences price target raised to $35 from $33 at Credit Suisse
• Avidity Biosciences Stock Soars after Positive RNA Data
• Avidity Biosciences announces results from Phase 1/2 MARINA trial
• Credit Suisse to hold a conference